FDA approves new treatments for heart disease caused by a serious rare disease, transthyretin mediated amyloidosis
U.S. Food and Drug Administration approved Vyndaqel (tafamidis meglumine) and Vyndamax (tafamidis) capsules for the treatment of the heart disease (cardiomyopathy) caused... Read More